Although the reasons were generally not reported, the most logical reason is that current PPARγ drugs have limited therapeutic windows in neurological disease treatment, i.e., a range of doses at which a medication is effective without unacceptable adverse events. This evidence concerns the gene PPARG and nervous system disorder.